National Heart, Lung, and Blood Institute (NHLBI): Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 25 Leukemia, Lymphocytic, Chronic, B-Cell studies with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor. 5 are open to participants now and 10 have results posted.

Early Phase 1 1Phase 1 7Phase 2 15No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 InhibitorNot yet recruitingNCT07796373Phase 2
• Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibRecruitingNCT07428707Early Phase 1
• Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or VenetoclaxRecruitingNCT05724121
• Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)RecruitingNCT03986034Phase 2
• Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT00923507
• Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04209621Phase 2Results posted
• Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)CompletedNCT03702231Phase 2Results posted
• HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)CompletedNCT03685708Phase 2Results posted
• Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03204188Phase 2Results posted
• A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLLActive, not recruitingNCT02514083Phase 2Results posted
• Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
• PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT01500733Phase 2Results posted
• Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLLCompletedNCT01145209Phase 2Results posted
• Stem Cell Transplantation for Patients With Cancers of the BloodCompletedNCT00467961Phase 2Results posted
• Methods to Enhance the Safety and Effectiveness of Stem Cell TransplantsCompletedNCT00378534Phase 2Results posted
• Epcoritamab in Chronic Lymphocytic Leukemia and Richter SyndromeActive, not recruitingNCT06676033Phase 1
• Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral InfectionsTerminatedNCT02231853Phase 1
• Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell TransplantationCompletedNCT02226861Phase 1
• Improving Blood Stem Cell Collection and Transplant ProceduresCompletedNCT01517035Phase 1/2
• A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy VolunteersCompletedNCT01117142
• A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid MalignanciesCompletedNCT00861510Phase 1
• Natural Killer Cells and Bortezomib to Treat CancerCompletedNCT00720785Phase 1
• Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic LeukemiaCompletedNCT00366418Phase 1
• The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood CancersCompletedNCT00001873Phase 2
• Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older AdultsCompletedNCT00001637Phase 2